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Introduction
Perfluoroalkyl substances (PFASs) are synthetic 
fluorinated compounds used in the manu-
facture of consumer and industrial products, 
such as food packaging, stain-resistant coatings 
for carpets and furniture, insecticides, and 
firefighting foams (Lau et al. 2007). Human 
exposure to PFASs can occur through 
ingestion of contaminated food (Fromme 
et al. 2009) and drinking water (Mak et al. 
2009), and ingestion or inhalation of PFAS-
contaminated dust and soil (Fromme et al. 
2009). Due to stable carbon-fluorine bonds, 
PFASs can persist in the environment and 
in humans (half-life of serum elimination 
~ 3–5 years) (Olsen et al. 2007). For example, 
despite the fact that the industrial produc-
tion of perfluorooctane sulfonate (PFOS) 
was discontinued in 2002 and reductions in 
perfluorooctanoate (PFOA) manufacturing 
emissions have been accomplished (U.S. EPA 
2014), these compounds are still detectable in 
the U.S. general population (≥ 12 years of age) 
(CDC 2015).
In vitro and in vivo studies suggest that 
PFASs may act as endocrine disruptors via 
a) alterations in estrogen- and androgen-
receptor function (Kjeldsen and Bonefeld-
Jørgensen 2013), b) activation of peroxisome 
proliferator-activated receptors (PPAR) α or γ 
(Hines et al. 2009; Zhang et al. 2014), c) inhi-
bition of the enzyme 11-β-hydroxysteroid 
dehydrogenase-2 (Ye et al. 2014), or 
d) disruption of thyroid hormone homeo-
stasis (Long et al. 2013). However, the 
few animal and human studies that have 
examined the association between prenatal 
PFAS exposure and adiposity have reported 
inconsistent findings. For example, one study 
in mice observed higher body weights in 
young adult female offspring after low-dose 
(0.01–0.3 mg/kg) prenatal exposures to 
PFOA (Hines et al. 2009), whereas another 
rodent study reported no associations (Ngo 
et al. 2014). Epidemiological studies from 
the United States and Denmark found that 
prenatal PFOA serum concentrations were 
associated with higher body mass index (BMI), 
waist circumference, and body fat in 8-year-
old boys and girls (Braun et al. 2016); and 
with overweight and high waist circumference 
in 20-year-old women (Halldorsson et al. 
2012), but not men. Additionally, a cohort 
study of Greenlandic and Ukrainian children 
reported associations of prenatal PFOA and 
PFOS serum concentrations with higher risk 
of waist-to-height ratio > 0.5 in girls ages 
5–9 years (Høyer et al. 2015). In contrast, 
a Danish cohort study reported that higher 
prenatal plasma PFOS and PFOA concentra-
tions were associated with small decrements 
in BMI and waist circumference in 7-year-old 
boys and girls (Andersen et al. 2013). To our 
knowledge, none of these prospective cohort 
studies used direct measures of adiposity, such 
as dual X-ray absorptiometry (DXA), nor did 
they examine markers of pregnancy hemo-
dynamics (e.g., albumin and renal function) 
and their potential role as confounders of the 
exposure-outcome association.
We examined associations of prenatal 
exposure to PFASs, including PFOA, 
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Background: Few studies have examined whether prenatal exposure to perfluoroalkyl substances 
(PFASs) is associated with childhood adiposity.
oBjective: We examined associations of prenatal exposure to PFASs with adiposity in early and 
mid-childhood.
Methods: We measured plasma PFAS concentrations in 1,645 pregnant women (median, 9.6 weeks 
gestation) enrolled in Project Viva, a prospective pre-birth cohort study in Massachusetts (USA), 
between 1999 and 2002. We assessed overall and central adiposity in 1,006 children in early child-
hood (median, 3.2 years) and 876 in mid-childhood (median, 7.7 years) using anthropometric and 
dual X-ray absorptiometry (DXA) measurements. We fitted multivariable linear regression models to 
estimate exposure-outcome associations and evaluated effect modification by child sex.
results: Median (25–75th percentiles) prenatal plasma perfluorooctanoate (PFOA), perfluoro-
octane sulfonate (PFOS), perfluorohexane sulfonate (PFHxS), and perfluorononanoate (PFNA) 
concentrations in children assessed in early childhood were 5.6 (4.1–7.7), 24.8 (18.4–33.9), 2.4 
(1.6–3.8), and 0.6 (0.5–0.9) ng/mL, respectively. Among girls, each interquartile range incre-
ment of prenatal PFOA concentrations was associated with 0.21 kg/m2 (95% CI: –0.05, 0.48) 
higher body mass index, 0.76 mm (95% CI: –0.17, 1.70) higher sum of subscapular and triceps 
skinfold thickness, and 0.17 kg/m2 (95% CI: –0.02, 0.36) higher DXA total fat mass index in 
 mid- childhood. Similar associations were observed for PFOS, PFHxS, and PFNA. We observed null 
associations for boys and early-childhood adiposity measures.
conclusions: In this cohort, prenatal exposure to PFASs was associated with small increases in 
adiposity measurements in mid-childhood, but only among girls.
citation: Mora AM, Oken E, Rifas-Shiman SL, Webster TF, Gillman MW, Calafat AM, 
Ye X, Sagiv SK. 2017. Prenatal exposure to perfluoroalkyl substances and adiposity in early and 
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PFOS, perfluorohexane sulfonate (PFHxS), 
and perfluorononanoate (PFNA), with 
adiposity in early and mid-childhood in a 
sample of mother–child pairs participating 




Project Viva is a prospective pre-birth cohort 
designed to study the extent to which events 
during early development affect health 
outcomes over the lifespan. Subject recruit-
ment and procedures for Project Viva have 
been described elsewhere (Oken et al. 2015; 
Sagiv et al. 2015). Briefly, between 1999 and 
2002, we recruited pregnant women at their 
first prenatal visit to Atrius Harvard Vanguard 
Medical Associates, a multi-specialty group 
practice in the Greater Boston area. Eligible 
women were English speaking, < 22 weeks of 
gestation, had singleton gestations, and had 
no plans to move away from the study area 
before delivery. Of the initial 2,128 women 
who delivered live-born singletons, 1,668 
(78%) provided a blood sample at their 
first prenatal visit, but only 1,645 (77%) 
had sufficient plasma for PFAS measure-
ments. Of these 1,645, 1,006 (61%) children 
attended an in-person early childhood visit 
(median age, 3.2 years; range, 2.9–6.1) at 
the study center or at home, and 876 (53%) 
children attended a mid-childhood visit 
(median age, 7.7 years; range, 6.6–10.9). We 
collected body composition data from DXA 
in 700 (80%) of the 876 children assessed 
in mid-childhood.
Mothers provided written informed 
consent at each study visit and children 
provided verbal assent at the mid-childhood 
visit. All study activities were approved by 
the institutional review boards of the partici-
pating sites. The involvement of the Centers 
for Disease Control and Prevention (CDC) 
laboratory was determined not to constitute 
engagement in human subjects research.
Plasma PFAS Concentrations
Plasma samples collected during the first 
prenatal visit (median, 9.6 weeks gesta-
t ion; 25–75th percenti les ,  8.7–10.9; 
range, 5.6–20.9) were shipped to the CDC 
(Atlanta, GA) for analysis. CDC staff quanti-
fied PFOA, PFOS, PFHxS, and PFNA in 
maternal plasma using on-line solid-phase 
extraction coupled with isotope dilution 
high-performance liquid chromatography–
tandem mass spectrometry (Kato et al. 2011). 
Limits of detection (LOD) were 0.2 ng/mL 
(PFOS) and 0.1 ng/mL (all other PFASs). We 
detected PFASs in 99–100% of plasma and 
values below the LOD were replaced with the 
LOD divided by the square root of 2.
Child Adiposity
We measured weight, height, hip and waist 
circumference, and skinfold thickness in 
early and mid-childhood, using procedures 
that have been published elsewhere (Boeke 
et al. 2013). Briefly, we measured height 
and weight using a calibrated stadiometer 
and scale. We calculated BMI as weight/
height2 and computed age- and sex-specific 
BMI z-scores and percentiles using U.S. 
national reference data (CDC 2000). We 
defined obesity as BMI ≥ 95th percentile, 
and overweight as BMI ≥ 85th and < 95th 
percentile (CDC 2000), and used BMI 
< 85th percentile as the comparison group. 
We measured hip and waist circumferences 
using a measuring tape and computed waist-
to-hip circumference ratios. We measured 
subscapular and triceps skinfold thicknesses 
using calipers and calculated the sum of the 
two thicknesses and the subscapular-to-triceps 
ratio. At age 7 years, children underwent 
whole body DXA scans (Discovery A Model; 
Hologic, Inc.) (Boeke et al. 2013). We calcu-
lated DXA fat mass, fat-free mass, and trunk 
fat mass indexes as mass/height2 (VanItallie 
et al. 1990).
We examined both indirect (BMI, 
skinfold thicknesses, and waist circumfer-
ence) and direct (DXA fat mass, total fat-free 
Table 1. Characteristics of study participants (after covariate imputation) [n (%)].
Characteristic
Children with early childhood data  
(n = 1,006) 
Children with mid-childhood data 
(n = 876) 
Maternal/family characteristics
Age at enrollment (years)
< 20 31 (3) 35 (4)
20–< 35 657 (65) 565 (64)
> 35 318 (32) 276 (32)
Race/ethnicity 
Black 116 (12) 134 (15)
White 737 (73) 600 (68)
Other 153 (15) 142 (16)
Married/living as married
No 76 (8) 82 (9)
Yes 930 (92) 794 (91)
Parity
0 478 (48) 421 (48)
1 367 (36) 316 (36)
≥ 2 161 (16) 139 (16)
Education 
< College graduate 292 (29) 281 (32)
College graduate 383 (38) 305 (35)
Graduate school 331 (33) 290 (33)
Annual household income (US$)
< 40,000 148 (15) 155 (18)
40,000–70,000 235 (23) 191 (22)
> 70,000 623 (62) 530 (60)
Prepregnancy BMI (kg/m2) 
Underweight (< 18.5) 27 (3) 27 (3)
Normal (18.5–24.9) 609 (61) 526 (60)
Overweight (25.0–29.9) 228 (23) 197 (22)
Obese (≥ 30) 142 (14) 126 (14)
Smoking status 
Never smoked 682 (68) 620 (71)
Former smoker 211 (21) 167 (19)
Smoked during pregnancy 113 (11) 89 (10)
Breastfeeding of the index child
No 116 (12) 94 (11)
Yes 890 (88) 782 (89)
Child characteristics
Sex 
Boys 531 (53) 454 (52)
Girls 475 (47) 422 (48)
BMI in early childhood (percentile)a
Underweight/normal (< 85th) 707 (72)
Overweight (85–< 95th) 188 (19)
Obese (≥ 95th) 93 (9)
BMI in mid-childhood (percentile)b
Underweight/normal (< 85th) 646 (74)
Overweight (85–< 95th) 114 (13)
Obese (≥ 95th) 111 (13)
BMI, body mass index.
aMissing data for 18 (1.8%) children in early childhood.
bMissing data for 5 (0.6%) children in mid-childhood.
Prenatal PFAS exposure and childhood adiposity
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mass, and trunk fat mass indexes) adiposity 
measures to better understand the exposure–
outcome association, reduce the likelihood of 
outcome misclassification, and improve our 
ability to compare our findings to those from 
previous studies. We also grouped adiposity 
measurements into overall adiposity (BMI, 
BMI z-scores, sum of subscapular and triceps 
skinfold thicknesses, DXA fat mass index, and 
DXA total fat-free mass index) and central 
adiposity (waist circumference, waist-to-hip 
circumference ratio, subscapular-to-triceps 
skinfold thickness ratio, and DXA trunk fat 
mass index), because we were interested in 
exploring the associations of PFASs with body 
fat distribution.
Potential Confounders and 
Predictors of Adiposity
Using in-person interviews and questionnaires 
during pregnancy, we collected information 
on maternal age, ethnicity, education, parity, 
smoking habits, marital status, dietary intake, 
and household income. We abstracted data 
on gestational weight gain (GWG), infant 
birth weight, and delivery date from medical 
records. We calculated prepregnancy BMI 
from self-reported height and weight. We 
computed GWG as the difference between 
prepregnancy weight and the last clinically 
recorded weight before delivery (median, 
~ 3 days before delivery; range, 1–30) and 
determined gestational age at birth using 
the date of the last menstrual period or a 
second trimester ultrasound if the two esti-
mates differed by > 10 days. We collected 
data on child’s physical activity, screen time, 
and fast food and soda intake using mailed 
 questionnaires and in-person interviews.
Pregnancy Hemodynamics
Plasma samples (from the same archived 
specimens used for quantification of PFASs) 
were analyzed by Children’s Hospital 
Boston Clinical and Epidemiologic Research 
Laboratory (Boston, MA) for albumin and 
creatinine, two markers of pregnancy hemo-
dynamics (Savitz 2014). PFASs have high 
binding affinity for albumin (D’Eon et al. 
2010). Furthermore, circulating albumin 
concentrations decrease during pregnancy, 
reflecting plasma volume expansion. We used 
plasma creatinine concentrations to compute 
glomerular filtration rate (GFR), a measure 
of the flow rate of filtered fluid through 
the kidney (Blackburn and Loper 1992) 
that increases during pregnancy and may 
confound the association between prenatal 
PFAS exposure and fetal growth (Morken 
et al. 2014; Verner et al. 2015). We used the 
Cockroft–Gault formula to compute GFR 
[GFR-CG = (140 – age) × pre-pregnancy 
weight (kg) × 1.04/plasma creatinine 
(μmol/L)] (Morken et al. 2014).
Statistical Analyses
We examined associations of prenatal plasma 
PFAS concentrations with adiposity measure-
ments using multivariable linear regression 
models. We also fitted generalized additive 
models (GAM) with penalized spline smooth 
terms for continuous exposures and visually 
assessed plotted splines to determine linearity 
of exposure–outcome associations. However, 
we found no evidence of nonlinear associations 
of prenatal PFAS concentrations with adiposity 
outcomes (data not shown, all pGAM > 0.05). 
We therefore included PFAS concentrations 
parameterized as continuous variables in all 
models, with point estimates representing the 
change in outcome for each interquartile range 
(IQR) increase in PFAS concentrations. We 
interpreted our effect estimates based on their 
magnitude and precision instead of relying 
solely on their statistical significance.
We fitted multivariable polytomous logistic 
regression models to examine the relation of 
prenatal plasma PFAS concentrations with 
relative risks of overweight and obesity, with 
underweight/normal as the reference outcome. 
In addition, we evaluated effect modification 
of the exposure–outcome associations by child 
sex by including an interaction term in the 
models and running sex-stratified analyses.
Covariates that are known predictors 
of childhood adiposity or strong potential 
confounders (i.e., maternal age, ethnicity, 
education, parity, prepregnancy BMI, timing of 
blood draw, child sex, child’s age at assessment) 
were identified based on the existing litera-
ture (Andersen et al. 2013; Braun et al. 2016; 
Halldorsson et al. 2012; Høyer et al. 2015) 
and included a priori in regression models. 
Other potential confounders (household 
income, maternal smoking status, duration 
of breastfeeding for index child, maternal diet 
during pregnancy, birth weight, gestational age 
at birth; child’s physical activity, screen time, 
and fast food and soda consumption) were 
selected using directed acyclic graphs and then 
explored separately with bivariate regression 
models. To the models with a priori covariates, 
we added, one at a time, covariates that were 
associated with the exposures and any of the 
outcomes in the bivariate analyses (p < 0.10). 
Additional covariates (i.e., household income) 
were included in the final model if they materi-
ally changed the PFAS coefficients. We used 
chained equations to impute missing covari-
ates (all of them missing < 10%) (Lubin et al. 
2004), but excluded study participants with 
missing exposure or outcome data for a given 
exposure–outcome analysis.
We conducted several sensitivity analyses 
to assess the robustness of our results. First, 
we added all four PFASs in the final models to 
examine co-pollutant confounding. Second, 
we included maternal albumin concentra-
tions and GFR individually to the final 
models to account for possible confounding 
by pregnancy hemodynamics. The inclusion 
of maternal albumin concentrations in the 
models could also be considered a similar 
procedure to the traditional adjustment for 
lipids for lipophilic chemicals (Abdelouahab 
et al. 2013), given that albumin is the major 
binding protein for PFASs. Because maternal 






n Median (P25–P75) n Median (P25–P75)
Exposure
Prenatal plasma PFAS concentrations (ng/mL) 
PFOS 1,006 24.8 (18.4–34.1) 876 24.7 (18.2–33.6)
PFOA 1,006 5.6 (4.1–7.7) 876 5.6 (3.9–7.6)
PFHxS 1,006 2.4 (1.6–3.8) 876 2.3 (1.6–3.7)
PFNA 1,006 0.6 (0.5–0.9) 876 0.6 (0.5–0.9)
Adiposity measurements
Early childhood
BMI (kg/m2) 988 16.4 (15.6–17.3)
BMI z-score 988 0.5 (–0.2–1.1)
Waist circumference (cm) 992 51.1 (49.2–53.4)
Waist-to-hip circumference ratio (× 100) 987 91.4 (86.8–94.7)
Sum of subscapular and triceps skinfold thickness (mm) 964 16.0 (13.8–18.8)
Subscapular-to-triceps skinfold thickness ratio (× 100) 964 62.8 (54.0–72.9)
Mid-childhood
BMI (kg/m2) 871 16.4 (15.4–18.2)
BMI z-score 871 0.4 (–0.3–1.1)
Waist circumference (cm) 873 58.3 (54.5–63.0)
Waist-to-hip circumference ratio (× 100) 861 87.2 (84.2–90.4)
Sum of subscapular and triceps skinfold thickness (mm) 873 16.6 (13.4–22.0)
Subscapular-to-triceps skinfold thickness ratio (× 100) 873 66.7 (58.1–80.6)
DXA total fat mass index (kg/m2) 700 3.8 (3.1–5.1)
DXA total fat-free mass index (kg/m2) 700 12.9 (12.1–13.9)
DXA trunk fat mass index (kg/m2) 700 1.2 (0.9–1.7)
Abbreviations: BMI, body mass index; DXA, dual X-ray absorptiometry; P25, 25th percentile; P75, 75th percentile; PFAS, 
perfluoroalkyl substance; PFHxS, perfluorohexane sulfonate; PFNA, perfluorononanoate; PFOA, perfluorooctanoate; 
PFOS, perfluorooctane sulfonate.
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PFAS concentrations have been positively 
associated with GWG (Ashley-Martin et al. 
2016) and GWG is an important determi-
nant of adiposity in childhood (Oken et al. 
2007), we also included GWG in the final 
models to explore its potential effect as 
mediator of the PFAS–adiposity associations. 
Last, we fitted linear regression models with 
generalized estimating equations (GEEs) for 
repeated outcome measures to examine longi-
tudinal relationships of PFAS concentrations 
with BMI, hip and waist circumference, and 
skinfold thickness across childhood.
Results
Participants’ Characteristics
Project Viva mothers were predominantly 
white (73%), younger than 35 years at the time 
of delivery (mean age ± SD = 32.5 ± 5.1 years), 
married or living as married (92%), multipa-
rous (53%), and with relatively high educa-
tional attainment (71% completed college or 
graduate school) and household income (62% 
had income > $70,000/year; Table 1). Median 
(25–75th percentiles) prenatal plasma PFOA, 
PFOS, PFHxS, and PFNA concentrations in 
children who were assessed in early childhood 
were 5.6 (4.1–7.7), 24.8 (18.4–34.1), 2.4 
(1.6–3.8), and 0.6 (0.5–0.9) ng/mL, respec-
tively (Table 2). PFAS concentrations were 
moderately to strongly correlated with each 
other [(range of Spearman correlation coef-
ficients (rs) = 0.44–0.74; see Table S1], but 
weakly correlated with maternal plasma GFR 
(rs = –0.11–0.28) and albumin concentra-
tions (rs = 0.11–0.26; data not shown). Most 
adiposity measurements were moderately to 
strongly correlated with each other (rs = 0.35–
0.98, excluding waist-to-hip and subscapular-
to-triceps skinfold ratios; see Table S2). 
Children who were assessed at early and mid-
childhood had very similar distributions of 
exposures, covariates, and outcomes of interest 
(Tables 1 and 2).
Mother–child pairs included in the present 
study did not differ substantially from the initial 
cohort (n = 2,128) on most attributes, including 
maternal age, education, ethnicity, prepreg-
nancy BMI, household income, and child sex 
and age at early or mid-childhood visits (Oken 
et al. 2015). Additionally, we did not observe 
material differences in prenatal plasma PFAS 
concentrations between all children who had 
their prenatal PFAS concentrations measured 
(n = 1,645) and children who participated in the 
early and/or mid-childhood assessments (data 
not shown).
Prenatal PFAS and Adiposity 
in Early Childhood
Associations between prenatal plasma PFAS 
concentrations and adiposity measurements 
in early childhood hovered at the null in both 
combined (all children) and sex-stratified 
analyses (most pint > 0.20; Table 3). Likewise, 
we did not observe consistent associations of 
prenatal PFAS concentrations with risk of 
overweight and obesity in early childhood 
(see Table S3).
Prenatal PFAS and Adiposity 
in Mid-Childhood
We did not find strong associations between 
prenatal plasma PFAS concentrations and 
adiposity in mid-childhood in analyses of 
boys and girls combined (Table 4). When 
we stratified by child sex, we observed null 
PFAS–adiposity associations among boys. 
However, among girls, we found small and 
consistent associations of prenatal PFAS 
concentrations with higher overall and central 
adiposity measures (Table 4). For example, 
among girls, higher PFOA concentra-
tions were associated with modest increases 
in BMI [β per IQR increase = 0.21 kg/m2; 
95% confidence interval (CI): –0.05, 0.48; 
pint = 0.20], sum of subscapular and triceps 
skinfold thickness (β = 0.76 mm; 95% CI: 
–0.17, 1.70; pint = 0.30), DXA total fat mass 
index (β = 0.17 kg/m2; 95% CI: –0.02, 0.36; 
pint = 0.31), waist circumference (β = 0.46 
cm; 95% CI: –0.29, 1.20; pint = 0.19), and 
subscapular-to-triceps skinfold thickness ratio 
(β = 1.66; 95% CI: –0.16, 3.47; pint = 0.08; 
see Figure S1). Similar findings were observed 
for PFOS, PFHxS, and PFNA (Table 4).
We observed that, among girls, those with 
higher prenatal PFAS concentrations were 
relatively more likely to be obese at 7 years 
(see Table S3). For example, IQR increases in 
prenatal PFHxS were associated with relative 
risks of 1.14 (95% CI: 0.97, 1.33; pint = 0.22) 
for obesity. Associations for PFASs and relative 
risk of obesity among boys hovered at the null.
Sensitivity Analyses
When we adjusted for all four PFASs in 
the same model, we observed mostly null 
PFAS–adiposity associations in early and 
Table 3. Associations of prenatal plasma PFAS concentrations with overall and central adiposity 
measurements in early childhood among all children and stratified by child sex [β (95% CI)].
Variable/PFAS metabolite All children Boys Girls pint
Overall adiposity
BMI (kg/m2)
PFOS 0.04 (0.05, 0.12) 0.02 (–0.11, 0.15) 0.04 (–0.08, 0.16) 0.56
PFOA 0.09 (–0.02, 0.19) 0.08 (–0.09, 0.26) 0.08 (–0.06, 0.21) 0.82
PFHxS 0.01 (–0.05, 0.06) 0.00 (–0.08, 0.08) 0.01 (–0.06, 0.08) 0.94
PFNA 0.02 (–0.07, 0.12) –0.05 (–0.18, 0.08) 0.07 (–0.05, 0.20) 0.20
BMI z-score
PFOS 0.03 (–0.03, 0.09) 0.02 (–0.08, 0.11) 0.04 (–0.04, 0.13) 0.50
PFOA 0.05 (–0.02, 0.12) 0.03 (–0.09, 0.15) 0.06 (–0.03, 0.15) 0.62
PFHxS 0.01 (–0.03, 0.05) 0.01 (–0.05, 0.07) 0.01 (–0.04, 0.05) 0.86
PFNA 0.02 (–0.05, 0.08) –0.03 (–0.12, 0.06) 0.05 (–0.03, 0.14) 0.22
Sum of subscapular and triceps 
skinfold thickness (mm)
PFOS –0.10 (–0.36, 0.16) –0.16 (–0.54, 0.21) –0.04 (–0.40, 0.32) 0.44
PFOA 0.19 (–0.12, 0.49) 0.41 (–0.08, 0.90) 0.04 (–0.36, 0.44) 0.53
PFHxS 0.16 (0.01, 0.31) 0.15 (–0.09, 0.38) 0.18 (–0.03, 0.38) 0.74
PFNA –0.01 (–0.28, 0.25) –0.25 (–0.63, 0.13) 0.18 (–0.20, 0.55) 0.16
Central adiposity
Waist circumference (cm)
PFOS 0.05 (–0.17, 0.27) –0.02 (–0.36, 0.31) 0.09 (–0.21, 0.38) 0.61
PFOA 0.31 (0.04, 0.57) 0.50 (0.06, 0.93) 0.14 (–0.18, 0.47) 0.24
PFHxS 0.03 (–0.10, 0.16) 0.01 (–0.20, 0.22) 0.04 (–0.13, 0.21) 0.93
PFNA –0.01 (–0.23, 0.22) –0.18 (–0.52, 0.15) 0.12 (–0.18, 0.42) 0.38
Waist-to-hip circumference ratioa
PFOS 0.00 (–0.35, 0.34) –0.16 (–0.69, 0.38) 0.14 (–0.31, 0.58) 0.67
PFOA 0.18 (–0.24, 0.59) 0.49 (–0.22, 1.19) –0.01 (–0.50, 0.49) 0.13
PFHxS –0.01 (–0.22, 0.20) 0.09 (–0.25, 0.42) –0.06 (–0.32, 0.19) 0.43
PFNA 0.19 (–0.17, 0.54) 0.34 (–0.20, 0.88) 0.12 (–0.34, 0.58) 0.45
Subscapular-to-triceps skinfold 
thickness ratioa
PFOS 0.25 (–0.70, 1.20) 0.55 (–0.76, 1.86) –0.01 (–1.40, 1.38) 0.60
PFOA 0.55 (–0.58, 1.68) 0.15 (–1.57, 1.88) 0.88 (–0.67, 2.44) 0.45
PFHxS –0.12 (–0.69, 0.45) –0.34 (–1.16, 0.48) 0.03 (–0.78, 0.83) 0.43
PFNA 0.50 (–0.48, 1.47) 0.51 (–0.82, 1.84) 0.45 (–1.00, 1.91) 0.85
Abbreviations: BMI, body mass index; PFAS, perfluoroalkyl substance; PFHxS, perfluorohexane sulfonate; PFNA, 
perfluorononanoate; PFOA, perfluorooctanoate; PFOS, perfluorooctane sulfonate. Effect estimates represent the mean 
change in the outcome for a change in PFAS concentrations from the 25th to the 75th percentile (or interquartile range). 
Models were adjusted for maternal age, race/ethnicity, education, parity, prepregnancy BMI, timing of blood draw, 
household income, child sex and age at outcome assessment. Children with data on BMI and BMI z-score: 988 (522 boys 
and 466 girls); sum of subscapular and triceps skinfold thickness and subscapular-to-triceps skinfold thickness ratio: 964 
(509 boys and 455 girls); waist circumference: 992 (521 boys and 471 girls); and waist-to-hip circumference ratio: 987 (519 
boys and 468 girls).
aRatios were multiplied by 100 to make estimates interpretable.
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mid-childhood (see Tables S4 and S5), 
possibly due to the moderate-to-strong 
correlation between PFASs and loss of preci-
sion. The inclusion of maternal plasma 
albumin concentrations during pregnancy 
(see Tables S6 and S7) and GWG (data not 
shown) in the models also attenuated most 
of the effect estimates, whereas including 
maternal GFR during pregnancy in the 
adjusted models marginally strengthened the 
associations (see Tables S6 and S7). We did 
not find consistent associations for prenatal 
PFAS plasma concentrations with repeated 
adiposity measurements in GEE analyses 
(see Table S8).
Discussion
We did not find strong associations between 
prenatal plasma PFAS concentrations and 
adiposity in children from Project Viva. We 
did observe modest associations of prenatal 
exposure to PFAS with overall and central 
adiposity measurements and risk of obesity 
in girls, but not boys, in mid-childhood. 
Notably, we found null associations between 
prenatal PFAS concentrations and adiposity 
earlier in childhood.
To our knowledge, this is one of the 
largest and most comprehensive studies to 
date on the potential obesogenic effects of 
prenatal exposure to PFASs. Few studies have 
prospectively examined the association of 
prenatal exposure to PFASs with adiposity 
measurements (Andersen et al. 2013; Braun 
et al. 2016; Halldorsson et al. 2012; Høyer 
et al. 2015), and there are some consisten-
cies between their findings and ours, particu-
larly stronger associations among females. 
A Danish study (n = 665) observed positive 
associations of prenatal PFOA serum concen-
trations with BMI and waist circumference in 
20-year-old women (Halldorsson et al. 2012), 
but not in men of the same age. Similarly, a 
study of Greenlandic and Ukrainian children 
5–9 years of age (n = 1,022) found that higher 
prenatal PFOA and PFOS serum concentra-
tions were associated with an increased risk of 
having a waist-to-height ratio > 0.5 (indirect 
measure of central adiposity) during child-
hood, particularly among girls (Høyer et al. 
2015). Other studies were less consistent, 
however. A prospective study of U.S. children 
8 years of age (n = 204) observed nonlinear 
associations of prenatal PFOA serum concen-
tration with higher adiposity measurements 
in both boys and girls (Braun et al. 2016). 
In addition, a Danish study (n = 811) found 
that higher prenatal plasma PFOS and PFOA 
concentrations were associated with slightly 
lower BMIs and waist circumferences in both 
boys and girls at age 7 years (Andersen et al. 
2013). Inconsistent findings could be attrib-
utable to differences in sociodemographic 
characteristics of the study populations, routes 
of exposure, maternal PFAS concentrations, 
outcome definitions, or analytical approaches.
In the present study, prenatal plasma PFAS 
concentrations showed small but positive asso-
ciations with both overall and central adiposity 
measurements in mid-childhood among girls. 
Central adiposity reflects intra-abdominal fat, 
which is more metabolically active than fat 
stored in other regions of the body (Björntorp 
1991). Nevertheless, recent studies have 
observed that overall and central adiposity 
measurements are similarly associated with 
cardiovascular disease events in adults (Taylor 
et al. 2010) and children (Lawlor et al. 2010).
Hemodynamic changes during pregnancy 
may affect circulating plasma concentrations 
Table 4. Associations of prenatal plasma PFAS concentrations with overall and central adiposity 
measurements in mid-childhood among all children and stratified by child sex [β (95% CI)].
PFAS/metabolite All children Boys Girls pint
Overall adiposity
BMI (kg/m2)
PFOS 0.16 (–0.04, 0.36) –0.02 (–0.32, 0.28) 0.28 (0.02, 0.55) 0.22
PFOA 0.13 (–0.10, 0.35) –0.06 (–0.45, 0.33) 0.21 (–0.05, 0.48) 0.20
PFHxS 0.04 (–0.08, 0.17) –0.07 (–0.27, 0.13) 0.11 (–0.05, 0.26) 0.15
PFNA 0.17 (–0.03, 0.36) 0.00 (–0.30, 0.30) 0.30 (0.06, 0.55) 0.31
BMI z-score
PFOS 0.07 (0.00, 0.13) 0.03 (–0.06, 0.13) 0.09 (–0.01, 0.18) 0.48
PFOA 0.04 (–0.03, 0.12) –0.04 (–0.17, 0.08) 0.09 (–0.01, 0.18) 0.06
PFHxS 0.01 (–0.03, 0.05) –0.01 (–0.07, 0.06) 0.01 (–0.04, 0.07) 0.52
PFNA 0.04 (–0.02, 0.11) 0.02 (–0.08, 0.11) 0.07 (–0.02, 0.16) 0.67
Sum of subscapular and triceps 
skinfold thickness (mm)
PFOS 0.47 (–0.16, 1.10) 0.07 (–0.80, 0.95) 0.75 (–0.18, 1.67) 0.37
PFOA 0.49 (–0.23, 1.20) –0.11 (–1.25, 1.04) 0.76 (–0.17, 1.70) 0.30
PFHxS 0.25 (–0.14, 0.64) –0.23 (–0.81, 0.36) 0.57 (0.03, 1.10) 0.06
PFNA 0.62 (0.01, 1.22) 0.13 (–0.74, 1.01) 1.01 (0.16, 1.86) 0.41
DXA total fat mass index (kg/m2)
PFOS 0.11 (–0.03, 0.25) 0.02 (–0.18, 0.22) 0.18 (–0.02, 0.38) 0.36
PFOA 0.13 (–0.02, 0.29) 0.05 (–0.22, 0.33) 0.17 (–0.02, 0.36) 0.31
PFHxS 0.04 (–0.04, 0.13) –0.04 (–0.18, 0.09) 0.09 (–0.02, 0.19) 0.09
PFNA 0.08 (–0.07, 0.23) –0.04 (–0.23, 0.16) 0.21 (–0.02, 0.44) 0.28
DXA total fat-free mass index 
(kg/m2)
PFOS 0.08 (–0.01, 0.18) 0.05 (–0.09, 0.19) 0.11 (–0.03, 0.24) 0.63
PFOA 0.06 (–0.05, 0.17) 0.04 (–0.15, 0.23) 0.07 (–0.06, 0.20) 0.60
PFHxS 0.00 (–0.05, 0.06) –0.02 (–0.11, 0.07) 0.01 (–0.06, 0.09) 0.52
PFNA 0.08 (–0.02, 0.18) 0.09 (–0.05, 0.22) 0.05 (–0.11, 0.21) 0.75
Central adiposity
Waist circumference (cm)
PFOS 0.34 (–0.19, 0.87) –0.02 (–0.78, 0.74) 0.60 (–0.15, 1.34) 0.32
PFOA 0.20 (–0.39, 0.80) –0.33 (–1.32, 0.66) 0.46 (–0.29, 1.20) 0.19
PFHxS 0.11 (–0.22, 0.43) –0.15 (–0.66, 0.36) 0.24 (–0.18, 0.67) 0.23
PFNA 0.31 (–0.19, 0.82) 0.11 (–0.66, 0.87) 0.50 (–0.17, 1.18) 0.79
Waist-to-hip circumference ratioa
PFOS 0.38 (–0.04, 0.80) 0.35 (–0.32, 1.03) 0.36 (–0.14, 0.86) 0.69
PFOA 0.11 (–0.36, 0.59) 0.02 (–0.86, 0.90) 0.19 (–0.32, 0.69) 0.79
PFHxS 0.19 (–0.07, 0.45) 0.06 (–0.40, 0.52) 0.24 (–0.04, 0.53) 0.74
PFNA 0.37 (–0.03, 0.77) 0.42 (–0.25, 1.10) 0.34 (–0.12, 0.80) 0.66
Subscapular-to-triceps skinfold 
thickness ratioa
PFOS 0.96 (–0.31, 2.23) 0.43 (–1.37, 2.24) 1.30 (–0.50, 3.10) 0.41
PFOA 1.02 (–0.41, 2.45) –0.35 (–2.71, 2.00) 1.66 (–0.16, 3.47) 0.08
PFHxS 0.74 (–0.04, 1.52) –0.50 (–1.70, 0.71) 1.61 (0.58, 2.65) < 0.01
PFNA 1.78 (0.57, 2.98) 1.23 (–0.58, 3.03) 2.17 (0.52, 3.83) 0.44
DXA trunk fat mass index (kg/m2)
PFOS 0.05 (–0.02, 0.11) 0.02 (–0.07, 0.10) 0.07 (–0.02, 0.16) 0.53
PFOA 0.06 (–0.01, 0.13) 0.05 (–0.07, 0.17) 0.07 (–0.01, 0.16) 0.55
PFHxS 0.02 (–0.02, 0.06) –0.02 (–0.07, 0.04) 0.04 (–0.01, 0.09) 0.12
PFNA 0.04 (–0.03, 0.11) 0.01 (–0.08, 0.09) 0.07 (–0.03, 0.18) 0.62
Abbreviations: BMI, body mass index; DXA, dual X-ray absorptiometry; PFAS, perfluoroalkyl substance; PFHxS, 
perfluoro hexane sulfonate; PFNA, perfluorononanoate; PFOA, perfluorooctanoate; PFOS, perfluorooctane sulfonate. 
Effect estimates represent the mean change in the outcome for a change in PFAS concentrations from the 25th to 
the 75th percentile (or interquartile range). Models were adjusted for maternal age, race/ethnicity, education, parity, 
prepregnancy BMI, timing of blood draw, household income, child sex and age at outcome assessment. Children with 
data on BMI and BMI z-score: 871 (450 boys and 421 girls); sum of subscapular and triceps skinfold thickness and 
subscapular-to-triceps skinfold thickness ratio: 873 (451 boys and 422 girls); DXA total fat mass, total fat-free mass, and 
trunk fat mass indexes: 700 (356 boys and 344 girls); waist circumference: 873 (453 boys and 420 girls); and waist-to-hip 
circumference ratio: 861 (448 boys and 413 girls).
aRatios were multiplied by 100 to make estimates interpretable.
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of PFASs (Fei et al. 2007; Verner et al. 
2015) and also predict unfavorable health 
outcomes among offspring (Savitz 2007). 
In our analyses, we assessed two markers of 
pregnancy hemodynamics, GFR and albumin, 
which have been examined in only two epide-
miological studies of PFAS exposure (Verner 
et al. 2015; Whitworth et al. 2012); both 
studies analyzed birth weight as their outcome 
of interest. When we included maternal GFR 
in the adjusted models, we observed a subtle 
strengthening of the effect estimates. It is 
possible that, because maternal plasma samples 
were collected early in pregnancy, changes 
in GFR may have not yet influenced PFAS 
significantly (Verner et al. 2015). Another 
possibility is that GFR does not confound 
associations with environmental chemi-
cals (Vesterinen et al. 2015) or that GFR 
confounds the associations with outcomes at 
birth but not at mid-childhood. When we 
adjusted for maternal albumin concentrations 
during pregnancy in our models, we noticed 
a slight attenuation of the effect estimates for 
all PFASs. A similar finding to the latter was 
observed in a Norwegian birth cohort study 
(n = 901) that examined the association 
between prenatal plasma PFOS concentrations 
and birth weight (Whitworth et al. 2012). 
These authors suggested that the estimates’ 
attenuation could be attributable to the 
binding affinity of PFAS for albumin and the 
association of maternal albumin concentra-
tions with adverse pregnancy outcomes, such 
as preterm birth (Whitworth et al. 2012).
Findings from our analyses and previous 
animal (Hines et al. 2009) and human 
(Halldorsson et al. 2012; Høyer et al. 2015) 
studies suggest that prenatal exposure to PFASs 
may affect males and females differently. 
However, we can only speculate as to what 
the biological basis for these sex differences is. 
Growing evidence suggests that the association 
of early-life exposure to certain environmental 
toxicants with placental functions and risk 
of disease later in life may vary by child sex 
(Gabory et al. 2013). Consequently, one expla-
nation could be that sex differences in the asso-
ciation between prenatal PFAS exposure and 
childhood adiposity are mediated by increased 
cortisol levels (Zhao et al. 2011) and linked 
to sex-specific effects on placental epigenetic 
processes, as has been reported with maternal 
stress (Mina et al. 2015).
Our study has several limitations. First, 
as in any cohort study, there was considerable 
loss to follow-up during the study period, 
which would have resulted in bias if attri-
tion had been related to both PFAS exposure 
and adiposity; yet we did not find differences 
in PFAS concentrations between children 
who had their prenatal PFAS concentrations 
measured and those who participated in the 
early and/or mid-childhood assessments. 
Second, we cannot rule out the possibility 
that some associations were due to chance. 
Nevertheless, given that conventional 
approaches for correcting for multiple 
comparisons have low efficiency and poor 
accuracy (Rothman et al. 2008), we were 
careful to point out patterns in our results 
rather than highlight only isolated findings. 
Third, because PFASs were moderately to 
strongly correlated in our study population, 
the inclusion of all four PFASs in the final 
models compromised the precision and plau-
sibility of the effect estimates and limited our 
ability to assess co-pollutant confounding. 
Fourth, the extent to which our results are 
generalizable to other populations may be 
limited because Project Viva participants had 
health insurance and were, on average, of 
higher socioeconomic status. Last, we cannot 
exclude the possibility that there is residual 
confounding by diet and that adiposity in 
early and mid-childhood could be also 
 influenced by postnatal exposure to PFASs.
The limitations of the present study are 
offset by notable strengths, including its large 
sample size and longitudinal design. We 
measured plasma PFAS concentrations early in 
pregnancy and evaluated children in early and 
mid-childhood using detailed outcome assess-
ments, including DXA measurements, which 
provide accurate results for total body compo-
sition and fat content and reduce the likeli-
hood of outcome misclassification. In addition, 
we were also able to examine and/or adjust for 
several important prenatal and postnatal factors 
such as markers of pregnancy hemodynamics, 
maternal education, prepregnancy BMI, and 
household income.
Conclusion
Our findings do not indicate a strong asso-
ciation between prenatal PFAS exposure and 
adiposity in early and mid-childhood, but 
rather modest associations with overall and 
central adiposity measurements and risk of 
obesity in mid-childhood among girls only. 
Given the ubiquity of PFASs in the environ-
ment and in human biological samples, it is 
of considerable public health importance to 
continue examining the endocrine-disrupting 
properties of these chemicals, even if only 
small effects are observed.
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